FDA Embraces Total-Time Pre-Market Review Goals, With Shared Accountability
FDA negotiators have warmed to the idea of total-time performance goals for the next round of medical device user fees, beginning in 2012, as long as FDA and industry share accountability for the time it takes to review new products.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
